For Q1 FY2026 (ended March 31, 2026), ProKidney Corp. reported revenue of $226,000, a decrease of 1.7% year-over-year. Net loss was $20.0 million, widening 19.7% from the prior year, while operating loss was $44.9 million, up 8.6%. The company held $101.9 million in cash and had negative equity of $1.02 billion.
•Revenue of $226,000, down 1.7% YoY.
•Net loss of $20.0 million, up 19.7% YoY.
•Operating loss of $44.9 million, up 8.6% YoY.
•Cash of $101.9 million; equity deficit of $1.02 billion.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
ProKidney Corp., a clinical-stage biotechnology company develops cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials.
Its portfolio also includes REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials, and REGEN-004 which is Phase I clinical trial. Founded in 2015, the company is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States. Its lead product candidate is rilparencel, an autologous selected renal cell therapy currently in Phase III clinical trials for advanced chronic kidney disease and type 2 diabetes. The company is also developing cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008, both in Phase III trials. Its pipeline includes earlier-stage candidates: REGEN-002, REGEN-003, and REGEN-007 in Phase II, and REGEN-004 in Phase I. These therapies aim to address the underlying causes of kidney disease by using the patient's own renal cells to restore kidney function.
Where is ProKidney Corp. (PROK) listed and in what currency?
ProKidney Corp. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol PROK. Its shares trade in US Dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Winston-Salem, North Carolina, and its operations are based in the US market.
What sector and industry does ProKidney Corp. (PROK) belong to?
ProKidney Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative cell therapies for chronic kidney diseases. Biotechnology companies like ProKidney typically engage in research and development of therapeutic products derived from biological sources, often requiring extensive clinical trials and regulatory approvals before commercialization.
Where is ProKidney Corp. (PROK) headquartered and what markets does it serve?
ProKidney Corp. is headquartered in Winston-Salem, North Carolina, United States. The company primarily serves the US market, as indicated by its country and region designations. Its clinical trials and development activities are focused on addressing chronic kidney diseases, which affect a significant portion of the US population. The company's therapies are designed to treat conditions like advanced chronic kidney disease and type 2 diabetes, which are prevalent in the US healthcare system.
What is the business model of ProKidney Corp. (PROK) and what are its key pipeline products?
ProKidney Corp. is a clinical-stage biotechnology company that does not yet have approved products or revenue from product sales. Its business model centers on developing cell therapies for chronic kidney diseases through rigorous clinical trials. The company's lead product, rilparencel, is an autologous selected renal cell therapy in Phase III trials for advanced chronic kidney disease and type 2 diabetes. It also has cryopreserved versions (REGEN-006 and REGEN-008) in Phase III, and earlier-stage candidates: REGEN-002, REGEN-003, and REGEN-007 in Phase II, and REGEN-004 in Phase I. The company's value depends on successful trial outcomes, regulatory approvals, and eventual commercialization, potentially through partnerships or direct sales.